Former Senior Vice President, Chief Financial Officer (former principal financial officer) · ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Manmeet Soni

A named executive officer of ALNYLAM PHARMACEUTICALS in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$3,308,932

Salary $314,442Stock awards $283,390

FY2018: $1,363,761

3rd of 7 named executive officers at Alnylam Pharmaceuticals by FY2019 total.

7 named officers on file for ALNYLAM PHARMACEUTICALS, FY2019

Manmeet Soni’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • ALNY’s disclosed peer group of 12 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ALNYLAM PHARMACEUTICALS’s whole pay program stands against its peers

  • ALNYLAM PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALNY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 23, 2020 (DEF 14A).

Free

Get Manmeet Soni’s full pay file as a PDF — free

More than this page: up to 10 years of Manmeet’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Manmeet Soni compensation by year

ALNYLAM PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as ALNYLAM PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$318,500$500,000$314,442
Bonus$100,000$50,000$0
Stock awards$0$0$283,390
Option awards$3,853,400$643,916$2,016,551
Non-equity incentive$165,620$160,000$0
Pension and deferred compensation$0$0$0
All other$44,180$9,845$694,549
Total$4,481,700$1,363,761$3,308,932

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ALNYLAM PHARMACEUTICALS, INC. DEF 14A filed March 23, 2020, accession 0001193125-20-082600, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ALNYLAM PHARMACEUTICALS, INC. filed document, accession 0001193125-20-082600. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2020.

$4.5M
$1.4M
$3.3M
FY17
FY18
FY19
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
PSU10,000$1,151,700—
Option2,979—$119.13
Option4,875—$119.13
Option20,000—$85.00
Option46,875—$52.61

Per the Outstanding Equity Awards at Fiscal Year-End table in ALNYLAM PHARMACEUTICALS, INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

ALNYLAM PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
John MaraganoreFormer Chief Executive Officer (principal executive officer)$7,317,856
Jeffrey PoultonExecutive Vice President, Chief Financial Officer (principal financial officer)$5,877,416
Manmeet Soni · this pageFormer Senior Vice President, Chief Financial Officer (former principal financial officer)$3,308,932
MBChB Yvonne L. GreenstreetChief Operating Officer$3,250,026
Barry GreeneFormer President$3,118,364
Akshay VaishnawPresident, Research and Development$3,100,953
Laurie KeatingExecutive Vice President, Chief Legal Officer and Secretary$2,421,680

The full ALNYLAM PHARMACEUTICALS compensation record

free company brief

This page is one person within ALNYLAM PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ALNYLAM PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ALNYLAM PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Manmeet Soni's compensation dossier · One-time report. No refunds.